Barclays analyst Luke Sergott raised the firm’s price target on Twist Bioscience to $26 from $20 and keeps an Overweight rating on the shares. The company reported a “clean beat-and-raise quarter” with modest growth on the core business bookings, continued sales strength, and gross margins “going in the right direction,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TWST:
- Twist Bioscience raises Q4 revenue view to $64M-$63M from $62M-$63M
- Twist Bioscience raises FY23 revenue view to $241M-$242M from $235M-$238M
- Twist Bioscience reports Q3 EPS ($1.01), consensus ($1.14)
- TWST Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Twist, Cancer Research Horizons team to advance research on cancer